Adma Biologics Inc (NASDAQ:ADMA) shares traded 30.93% higher at $15.96 on Wall Street last session.
ADMA stock price is now 37.87% away from the 50-day moving average and 129.12% away from the 200-day moving average. The market capitalization of the company currently stands at $3.72B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On October 13, 2022, Mizuho recently initiated its ‘Buy’ rating on the stock quoting a target price of $5, while ‘Raymond James’ rates the stock as ‘Strong Buy’
In other news, Grossman Adam S, President,CEO, and Interim CFO sold 100,000 shares of the company’s stock on Jun 14 ’24. The stock was sold for $1,071,980 at an average price of $10.72. Upon completion of the transaction, the President,CEO, and Interim CFO now directly owns 2,081,475 shares in the company, valued at $33.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 19 ’24, Director ELMS STEVE sold 411,829 shares of the business’s stock. A total of $2,503,920 was realized by selling the stock at an average price of $6.08. This leaves the insider owning 2,115,671 shares of the company worth $33.77 million. A total of 3.42% of the company’s stock is owned by insiders.
During the past 12 months, Adma Biologics Inc has had a low of $3.06 and a high of $14.03. As of last week, the company has a debt-to-equity ratio of 0.75, a current ratio of 6.87, and a quick ratio of 2.80. The fifty day moving average price for ADMA is $11.7077 and a two-hundred day moving average price translates $7.030275 for the stock.
The latest earnings results from Adma Biologics Inc (NASDAQ: ADMA) was released for 2024-06-30. The net profit margin was 10.53% and return on equity was 20.77% for ADMA. The company reported revenue of $107.19 million for the quarter, compared to $60.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 78.29 percent.
